Biodexa announces successful appeal of nasdaq delisting

Exhibit 99.1 october 15, 2024 biodexa announces successful appeal of nasdaq delisting biodexa pharmaceuticals plc. (the “company”) (nasdaq: bdrx), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced today that a nasdaq hearings panel (the “panel”) has granted the company's request for an extension of time to demonstrate compliance with the $1.00 minimum bid price requirement for continued listing on nasdaq stock market llc (“nasdaq”) set forth in nasdaq listing rule 5550(a)(2) (the “minimum bid price requirement”).
BDRX Ratings Summary
BDRX Quant Ranking